Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy, Biologic therapy.

Cancer Center, Warsaw, Poland.

Survival: monthsCountry:Poland
Toxiciy Grade:5City/State/Province:Warsaw
Treatments:Chemotherapy, Biologic therapyHospital:Cancer Center
Drugs:Journal:Link
Date:Mar 2014

Description:

Patients:
This phase 2 study involved castration-resistant prostate cancer patients who were divided into two separate treatment groups. Group A consisted of 98 patients with a median age of 69.07 years. Group B had 51 patients with a median age of 69.97 years.

Treatment:
Patients in group A were treated with the chemotherapy agent docetaxel and the biologic therapy called LY2181308, an antisense surviving oligonucleotide that inhibits the surviving protein to help cause cell death.

Patients in group B were treated with docetaxel alone.

Toxicities:
There were three treatment-related deaths in group A due to unspecified causes. Grade 4 neutropenia and leukopenia were also reported.

The most severe toxicities were grade 4 neutropenia and leukopenia. Grade 3 fatigue was also reported.

Results:
The median overall survival rates for group A and B were 27.04 and 29.04 months, respectively.

Support:
This study was supported by Eli Lilly.

Correspondence: Dr. Paweł Wiechno; email: [email protected]



Back